Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks

Autor: Frank Mulindwa, Jean-Marc Schwarz, Nele Brusselaers, Martin Nabwana, Robert Bollinger, Allan Buzibye, Willington Amutuhaire, George Yendewa, Eva Laker Agnes Odongpiny, Ronald Kiguba, Barbara Castelnuovo

Publikováno v: BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-10 (2024)

Abstract Background The Uganda ministry of Health recommends frequent blood glucose monitoring for the first six months on dolutegravir, in people with HIV (PWH) having pre-diabetes mellitus (pre-DM). We sought to determine if indeed PWH with pre-dia

Externí odkaz: https://doaj.org/article/d513a66e06a44a759aed8f18c4995609

Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults

Autor: Frank Mulindwa, Barbara Castelnuovo, Nele Brusselaers, Martin Nabwana, Robert Bollinger, Allan Buzibye, Eva Laker Agnes Odongpiny, Ronald Kiguba, Jean-Marc Schwarz

Publikováno v: AIDS Research and Therapy, Vol 20, Iss 1, Pp 1-8 (2023)

Abstract Background The Uganda Ministry of Health issued restrictive guidelines on the use of dolutegravir (DTG) in persons stratified to have a heightened risk of diabetes mellitus. This followed multiple reports of persons with HIV (PWH) presenting

Externí odkaz: https://doaj.org/article/74736fa00a924e2fa2b63e4e25056a4b

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial

Autor: Nicholas I Paton, Joseph Musaazi, Cissy Kityo, Stephen Walimbwa, Anne Hoppe, Apolo Balyegisawa, Jesca Asienzo, Arvind Kaimal, Grace Mirembe, Abbas Lugemwa, Gilbert Ategeka, Margaret Borok, Henry Mugerwa, Abraham Siika, Eva Laker A Odongpiny, Barbara Castelnuovo, Agnes Kiragga, Andrew Kambugu, Daniel Kiiza, John Kisembo, John Nsubuga, Max Okwero, Rhona Muyise, Claire Nasaazi, Dridah L. Nakiboneka, Josephine Namusanje, Theresa Najjuuko, Timothy Masaba, Timothy Serumaga, Adolf Alinaitwe, Allan Arinda, Angela Rweyora, Mary Goretti Kangah, Mariam Kasozi, Phionah Tukumushabe, Rogers Akunda, Shafic Makumbi, Sharif Musumba, Sula Myalo, John Ahuura, Annet Mary Namusisi, Daniel Kibirige, Francis Kiweewa, Habert Mabonga, Joseph Wandege, Josephine Nakakeeto, Sharon Namubiru, Winfred Nansalire, Abraham Mosigisi Siika, Charles Meja Kwobah, Chris Sande Mboya, Martha Mokeira Bisieri Mokaya, Mercy Jelagat Karoney, Priscilla Chepkorir Cheruiyot, Salinah Cherutich, Simon Wachira Njuguna, Viola Cherotich Kirui, Ennie Chidziva, Godfrey Musoro, James Hakim, Joyline Bhiri, Misheck Phiri, Shepherd Mudzingwa, Tadios Manyanga, Anchilla Mary Banegura, Betty Agwang, Brian Isaaya, Constantine Tumwine, Eva Laker A. Odongpiny, Nicholas Paton, Peter Senkungu, Yvonne Kamara, Mathius Amperiize, Elizabeth Allen, Charles Opondo, Perry Mohammed, Willemijn van Rein-van der Horst, Yvon Van Delft, Fafa Addo Boateng, Doreen Namara, Pontiano Kaleebu, Sylvia Ojoo, Tapiwanashe Bwakura, Milly Katana, Francois Venter, Sam Phiri, Sarah Walker

Publikováno v: The Lancet HIV. 9:e381-e393

WHO guidelines recommend dolutegravir plus two nucleoside reverse transcriptase inhibitors (NRTIs) for second-line HIV therapy, with NRTI switching from first-line tenofovir to zidovudine. We aimed to examine whether dolutegravir is non-inferior to d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9294a359496eae0df6d04748de07b343
https://doi.org/10.1016/s2352-3018(22)00092-3